Based on published evidence regarding osimertinib use in the double-blind, phase III ADAURA clinical trials, routine molecular biomarker testing of EGFR mutation is now recommended not only for patients with advanced or metastatic NSCLC but also for patients with completely resected stage IB-IIIA NSCLC according to the NCCN guidelines [14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.